Abstract 449P
Background
Breast cancer is the most common malignant tumor in women worldwide. Among the molecular subtypes of breast cancer, triple negative breast cancer (TNBC) is associated with worse prognosis and it lacks targetable hormonal receptor. In TNBC, androgen receptor (AR) positivity is about 25%-75% and would get potential benefit from anti-androgen therapy. The aims of this study are to know the occurrence of TNBC cases at Medical Oncology Department, YGH, and to know the AR status in TNBC cases.
Methods
This is a hospital-based, cross sectional descriptive study. All TNBC cases attending Medical Oncology Department, YGH, were collected from January 2019 to December 2019. Immunohistochemistry (IHC) for androgen receptor was done by peroxidase anti-peroxidase method.
Results
Among 808 breast cancer patients attended during study period, 515 patients were available for IHC testing and 88 patients were TNBC subtype. In those patients, 61 TNBC cases were included in this study; 22 patients were AR positive and 39 patients were AR negative. In TNBC, the youngest was 33, the eldest was 73 and median age was 53. Nine patients were <40 years of age. In histology, invasive ductal carcinoma was the commonest (91.8%). Regarding staging, unlike developed countries, advanced stage (64%) was the most common stage. Among AR positive patients, 23% were <40 years of age and 77% were ≥40 years. sixty eight percents of patients presented in advanced stage. In patients with negative AR status, 10% were <40 years of age and 90% were ≥40 years of age. Regarding the stage, 38% were early stage and 62% were advanced stage.
Conclusions
Although the risk of breast cancer increases with age, many younger patients were included in this study, reflecting that the trend is changing. Most patients presented at late stage and this points out that our population have limited knowledge about breast cancer. In this study, AR negativity (64%) is much more than that of positivity (36%), there were much younger patients in AR positive subgroup and not much association was seen between AR and histology. This study shows fundamental knowledge regarding AR status in TNBC in Myanmar.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ministry of Health.
Funding
Ministry of Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO11 - Satisfactory response after Rituximab-Bendamustin in Poor Performance Status Geriatric with Relapsed DLBCL
Presenter: Yasjudan Putra
Session: Poster viewing 06
YO12 - Allogeneic hematopoietic stem cell transplant in a case of acute myeloid leukaemia with end stage renal disease
Presenter: DEVYANI SURANGE
Session: Poster viewing 06
YO13 - Rosai-Dorfman Disease Presenting with Multiple Contiguous Lymphadenopathy: A Case Report
Presenter: Lean Marx Maaño
Session: Poster viewing 06
YO15 - Nasopharyngeal carcinoma in pregnancy: A Case Report
Presenter: Mary Antonette Ong
Session: Poster viewing 06
YO16 - New onset SIADH masquerading progression in esthesioneuroblastoma
Presenter: Muthu Manikandan
Session: Poster viewing 06
YO17 - Olfactory Neuroblastoma with Cervical Lymph Node Metastases in a 21- Year old Filipino Woman: A Case Report
Presenter: Mary Antonette Ong
Session: Poster viewing 06
YO18 - Challenges in Provision of Patient centered care with a Practical approach in a Resource-limited setting - Steven Johnson Syndrome – Toxic Epidermal Necrolysis (SJS-TEN) overlap related to Phenytoin use and review of logistical challenges related to care provision - a Case Report.
Presenter: Rahul D. Arora
Session: Poster viewing 06
YO19 - Posterior Reversible Encephalopathy Syndrome associated with Pharmacological management of Bowel obstruction at the end of life – a review of two cases separated by 5 years
Presenter: Rahul D. Arora
Session: Poster viewing 06
YO20 - A case of drug-induced large vessel vasculitis with hoarseness as the chief complaint caused by pegfilgrastim during chemotherapy
Presenter: Takuya Sato
Session: Poster viewing 06
YO23 - Neo-adjuvant immunotherapy in operable non-small cell lung carcinoma
Presenter: Padmini S N
Session: Poster viewing 06